
|Articles|September 18, 2015
Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
There are many clinical trial opportunities, Tolaney says, before surgery.
Advertisement
Sara M. Tolaney, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer.
“[There are] lots of potential clinical trial opportunities prior to surgery because we do have this question about whether or not platinum therapy is beneficial,” Tolaney says.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Every FDA Oncology Approval From November 2025
2
Reflecting on My Sister’s Final Days After Years of Unexpected Rebounds
3
Chemo Side Effects for Breast Cancer Led to Weeks in the Hospital
4
First Annual Blood Cancer Heroes Honors Leaders, Advocates and Survivors
5





